1. Sasanlimab combination significantly improves EFS in BCG-Naïve, high-Risk non-Muscle invasive bladder cancer

On April 26, 2025, Pfizer announced results from the Phase 3 CREST trial of sasanlimab, an investigational anti-PD-1 monoclonal antibody, in combination with standard of care (SOC) Bacillus Calmette-Guérin (BCG) as induction therapy with or without maintenance in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC). The trial met its primary endpoint of event-free survival (EFS) by investigator assessment, demonstrating a clinically meaningful and statistically significant improvement with sasanlimab combination. There was a 32% reduction in the risk of disease-related events, including high-grade disease recurrence or progression. Moreover, the probability of being event-free at 36 months was 82.1% (95% CI, 77.4-85.9) with sasanlimab in combination with BCG (induction and maintenance), and 74.8% (95% CI, 69.7-79.2) with BCG alone.

Link: https://www.pfizer.com/news/press-release/press-release-detail/pfizers-sasanlimab-combination-significantly-improves-event

2. Xofluza® control the transmission of the influenza virus within households

On 23 April, 2025, Roche published a detailed analysis of the phase III CENTERSTONE trial of Xofluza® (baloxavir marboxil) in controlling influenza virus infection. Xofluza (baloxavir marboxil) works by inhibiting the cap-dependent endonuclease (CEN) enzyme, thus stopping viral replication. The trial met its primary endpoint, showing that a single oral dose of Xofluza taken by people infected with influenza reduced 32% of the chances that an untreated household member being transmitted. As a secondary endpoint, Xofluza also showed a clinically meaningful reduction in the transmission-related symptoms.

Link: https://www.roche.com/media/releases/med-cor-2025-04-25

3. Cobenfy improved symptoms of schizophrenia patients with no significance

On 22 April, 2025, BMS announced that results from the Phase 3 ARISE trial evaluating the efficacy and safety of Cobenfy (xanomeline and trospium chloride) as an adjunctive treatment to atypical antipsychotics in adults with inadequately controlled symptoms of schizophrenia. Xanomeline targets muscarinic receptors in the brain, specifically M1 and M4 receptors, and trospium chloride cannot penetrate the blood-brain barrier and target peripheral organs to minimise potential side effects.

In the Phase 3 trial, adjunctive Cobenfy treatment demonstrated a 2.0-point reduction in the Positive and Negative Syndrome Scale (PANSS) total score compared to placebo with an atypical antipsychotic at Week 6, which did not reach the threshold for statistical significance for the primary endpoint (P = 0.11). The secondary endpoint of change in Personal and Social Performance Scale (PSP) was also not significant. In summary, preliminary analyses suggest that Cobenfy as an adjunctive treatment was associated with improvements in symptoms of schizophrenia, but significance was not achieved.

Link: https://news.bms.com/news/corporate-financial/2025/Bristol-Myers-Squibb-Announces-Topline-Results-from-Phase-3-ARISE-Trial-Evaluating-Cobenfy-xanomeline-and-trospium-chloride-as-an-Adjunctive-Treatment-to-Atypical-Antipsychotics-in-Adults-with-Schizophrenia/default.aspx

4. TAR-200 showed promising efficacy in treating certain types of bladder cancer

On 26 Apr, 2025, Johnson & Johnson announced new data from cohort 2 and cohort 4 of the Phase 2b SunRISe-1 study evaluating TAR-200 monotherapy for patients with certain types of bladder cancer.TAR-200 is an investigational intravesical drug delivery system designed to provide sustained local release of gemcitabine in the bladder.

In cohort 2, both bladder cancer patients with or without papillary tumours were recruited. Among the 85 enrolled patients, 82.4% achieved a complete response, with 52.9% of responders maintaining a complete response at one year. The median duration of response was 25.8 months, and 86.6% of responders remained cystectomy-free at one year.

In cohort 4, only bladder cancer patients with papillary tumours were analysed. 85.3% and 81.1% disease-free survival rates were achieved at six and nine months, respectively. Moreover, 94.2% of patients avoided radical cystectomy at a median follow-up of 12.8 months, which means those patients were able to preserve their bladders.

Link: https://www.jnj.com/media-center/press-releases/johnson-johnsons-tar-200-monotherapy-demonstrates-highest-complete-response-rate-with-sustained-clinical-benefits-in-patients-with-certain-types-of-bladder-cancer

https://www.jnj.com/media-center/press-releases/johnson-johnsons-tar-200-monotherapy-achieves-high-disease-free-survival-of-more-than-80-percent-in-bcg-unresponsive-high-risk-papillary-nmibc

5. Enhertu plus pertuzumab showed superior PFS over THP in first-line HER2-positive metastatic breast cancer

On 21 Apr, 2025, Astra Zeneca and Daiichi Sankyo announced DESTINY-Breast09 Phase III trial results that showed Enhertu (trastuzumab deruxtecan) in combination with pertuzumab demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to a taxane, trastuzumab and pertuzumab (THP) as a first line treatment for patients with HER2-positive metastatic breast cancer. There were improvements in progression-free survival (PFS) across all pre-specified patient subgroups with Enhertu in combination with pertuzumab. The key secondary endpoint of overall survival (OS) had not matured yet. However, the interim OS data showed an early trend favouring the Enhertu combination compared with THP.

Link: https://www.astrazeneca.com/media-centre/press-releases/2025/enhertu-combination-improved-pfs-in-1l-her-positive-mbc.html

6. Trodelvy® plus Keytruda® significantly improved PFS over Keytruda and chemotherapy in PD-L1+ metastatic triple-negative breast cancer

On 21 Apr, 2025, Gilead Sciences announced positive results from the Phase 3 ASCENT-04/KEYNOTE-D19 study. Trodelvy® (sacituzumab govitecan-hziy) plus Keytruda® (pembrolizumab) significantly improved progression-free survival (PFS) compared to Keytruda and chemotherapy in patients with unresectable locally advanced or metastatic triple-negative PD-L1+ breast cancer. Overall survival (OS) is a key secondary endpoint and was not mature at the time of the PFS primary analysis. Trodelvy is an antibody-drug conjugate (ADC) targeting cancer cells which express Trop-2 proteins. It delivers a potent cytotoxic drug, SN-38, to these cells, leading to cell death.

Link: https://www.gilead.com/news/news-details/2025/trodelvy-plus-keytruda-demonstrates-a-statistically-significant-and-clinically-meaningful-improvement-in-progression-free-survival-in-patients-with-previously-untreated-pd-l1-metastatic-trip